Artículos del autor

solaci

Structural heart disease

Leading Manufacturer of Balloon-Expandable Valves Launches Self-Expanding Device

Edwards Lifesciences could have been satisfied after the success of the PARTNER trials and the improvements to...
solaci -
Structural heart disease

Mild Leaks: TAVR’s Silent Enemies

Courtesy of Dr. Carlos Fava. Even though the presence of paravalvular regurgitation (PVR) has been reduced, thank to...
solaci -
Structural heart disease

Who Lives Longer After TAVR, Men or Women?

Courtesy of Dr. Carlos Fava. Currently, some small observational studies and a meta-analysis suggest that women experience more short-term...
solaci -
Acute coronary syndromes

Incomplete Revascularization Does Not Mean the Same Thing for All Patients

Several studies show that patients with multivessel lesions who undergo angioplasty with incomplete revascularization experience more events,...
solaci -
Mitral valve

Transcatheter Mitral Valve Replacement Devices Multiply

The Transcatheter mitral valve replacement has been established as gold standard for patients with intermediate or high risk...
solaci -
Other

Five-Year Outcomes for Appendage Closure

The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial...
solaci -
Chronic Ischemic cardiopathy

New FFR Measuring Device to Guide Coronary Revascularization with Our Preferred Wire

Measuring fractional flow reserve (FFR) with a 0.014 pressure wire is the standard to assess the functional significance...
solaci -
Acute coronary syndromes

The CULPRIT-SHOCK Study Is Finally Published in NEJM and It Is Bound to Change Guidelines

During SOLACI’s coverage of the TCT 2017 Congress in Denver, Colorado, we already mentioned some of the...
solaci -